Research and Developments


June 1, 2012

Summary of Research and Developments in Macular Degeneration, 2011-2012

Posted in: Research and Developments

by Dan Roberts June 2012 Introduction Here is MD Support’s summary of the the past twelve months of significant research and development in the field of macular degeneration. We begin with the field that has been making the most news: pharmacology. _______________________________ PHARMACOLOGY SEP: Infection Risk From Repackaged Avastin The big pharmaceutical news of the
read more »

April 22, 2012

IL-18 Can Prevent Inflammation in the Retina

Posted in: Research and Developments

by Dan Roberts Updated April 2014 A new finding by researchers at Trinity College Dublin may lead to another treatment for wet AMD. Inflammation in the retina results from blood vessel development, and the natural component named IL-18 has been found to keep the process under control. By injecting the chemical into the eye, or
read more »

March 11, 2012

What Is Macular Degeneration?

Posted in: Daily Living, Eye Conditions, Health and Nutrition, Low Vision Rehabilitation, Research and Developments, Therapies, Treatments, and Procedures

by Dan Roberts (Updated April 29, 2015) (Reviewed by Martin A. Mainster, Ph.D., M.D., FRCOphth) Audio/visual presentations on all related subjects Recommended books: The First Year: Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts Macular Degeneration: The Complete Guide to Saving and Maximizing Your Sight by Lylas Mogk, M.D.
read more »

February 28, 2012

Fenretinide For Treatment of Dry MD and Stargardt’s Disease

Posted in: Research and Developments

by Dan Roberts (Updated February 28, 2012) Fenretinide (RT-101), a drug that has been used to treat certain cancers, rheumatoid arthritis, acne, and psoriasis, has been found to also slow the production and accumulation of a toxin that leads to vision loss in Stargardt’s patients. The toxin, called A2E, is a byproduct of vitamin A,
read more »

February 9, 2012

New Radiation Treatment for Wet AMD

Posted in: Research and Developments

by Dan Roberts [It was reported on 2/9/12 that Phase III of this study did not meet it’s primary endpoint at 2 years. The information in this article describes the progress up to that point.] NeoVista, Inc. announced on June 17, 2007 the official commencement of the CABERNET (Cnv secondary to Amd treated with BEta
read more »

February 2, 2012

New Treatment for Dry AMD Using HuCNS Stem Cells

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single
read more »

June 1, 2011

AMD Report From ARVO 2011

Posted in: Research and Developments

by Dan Roberts It is important to note at the outset of this report that patients are highly respected across the professional board for their willingness to act as pioneers in the ongoing research. Our participation in clinical trials is greatly appreciated by the researchers. That having been said, here are latest updates on research
read more »

June 1, 2011

Summary of Research and Developments in Macular Degeneration, 2010-2011

Posted in: Research and Developments

by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything
read more »

May 30, 2011

Encapsulated Cell Technology (ECT)–A New Drug Delivery System

Posted in: Research and Developments

by Dan Roberts Updated March 30, 2015 A means of delivering drugs into the retina on a time release basis is being developed and proven safe and effective. It is achieved by a method called Encapsulated Cell Technology (ECT), being tested by Neurotech SA with support from the National Eye Institute (NEI), Bethesda, Maryland. A
read more »

April 22, 2011

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

Posted in: Research and Developments

The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use
read more »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann